- Home
- KIDS vs EYPT Comparison
KIDS vs EYPT Comparison
Compare KIDS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 1.5B |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KIDS | EYPT |
|---|---|---|
| Price | $17.05 | $17.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $24.75 | ★ $29.60 |
| AVG Volume (30 Days) | 226.5K | ★ 1.3M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,410,000.00 | $42,339,000.00 |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.90 | N/A |
| 52 Week Low | $15.28 | $3.91 |
| 52 Week High | $27.60 | $19.11 |
Technical Indicators
Market Signals| Indicator | KIDS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 66.36 |
| Support Level | $17.18 | $16.52 |
| Resistance Level | $18.36 | $17.40 |
| Average True Range (ATR) | 0.72 | 1.08 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 7.60 | 71.27 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.